The pharmaceutical industry has called for abolishing “off-year” drug price revisions in the run-up to the formulation of the 2024 Basic Policy on Economic and Fiscal Management and Reform (honebuto) later in June. It appears that its lobbying efforts have…
HOME > LATEST
LATEST
-
BUSINESS Chugai Offers 5% Pay Raise in 30-Year-Old Model Case
April 4, 2024
-
BUSINESS Mochida, Meiji Adds China for Epadel Sales Collaboration
April 4, 2024
-
BUSINESS Eisai to Divest Rights to 2 CNS Drugs to UK’s CNX in France, Algeria
April 4, 2024
-
BUSINESS Sawai Closes Sale of US Business to Taiwan CDMO
April 4, 2024
-
ORGANIZATION PhRMA Hails 2024 Reform, but Says Full Picture Unchanged as 50% of Patented Meds Still Face Cuts
April 4, 2024
-
REGULATORY Offset Technology-Driven Cost Rise with Spending Reforms: Govt Economic Estimate
April 3, 2024
-
ORGANIZATION Pharma Labor Group Makes Direct Plea to Lawmakers against Off-Year Price Cuts
April 3, 2024
-
REGULATORY Japan Health Minister Hints Positive Stance on Off-Year Price Revisions
April 3, 2024
-
REGULATORY Japan Govt Ends COVID Vaccine Supply as Emergency Program Winds Up
April 3, 2024
-
BUSINESS Sumitomo Offloads Entire Stake in Roivant as Earnings Tank
April 3, 2024
-
BUSINESS Daiichi’s TROP2 ADC Accepted for US FDA Review in Breast Cancer
April 3, 2024
-
REGULATORY Opposition Party Head Calls for Rethink of Public Health Coverage in Japan
April 3, 2024
-
COMMENTARY With Honebuto 2024 Looming, Now Is the Time to Revisit Social Security Spending
April 2, 2024
-
REGULATORY Japan Finalizes Generic Info Disclosure Guidelines for Company Indicator Rule
April 2, 2024
-
REGULATORY Japan Revises GMP Inspection Guide after Generic Manufacturing Issues
April 2, 2024
-
REGULATORY Japan’s Amended Next-Gen Medical Infrastructure Law Takes Effect
April 2, 2024
-
ORGANIZATION Wholesaler Group Launches Database for Unit Price-Based Negotiations
April 2, 2024
-
BUSINESS Axcelead-Teijin Drug Discovery Joint Venture Now Up and Running
April 2, 2024
-
BUSINESS MS Med Copaxone Transferred to Teva Takeda Pharma
April 2, 2024
-
BUSINESS Takeda to Hand Over Nihon Pharma to Alinamin in July
April 2, 2024
ページ
The pharmaceutical industry is ever-changing. Recruiters must evolve accordingly and prepare well in advance for future talent needs.This means predicting the changes and trends that will impact the market, industry, and your organization, and how this will affect talent requirements.…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…